This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Medtronic (MDT) Boosts Diabetes Management via New Infusion Set
by Zacks Equity Research
Medtronic's (MDT) recently introduced Medtronic Extended infusion set with longer wearability enhances convenience and comfort, thus improving diabetes care.
Dental Market Shows Strength Despite Pandemic: 3 Stocks to Watch
by Trina Mukherjee
Let's keep a watch on three lucrative stocks, XRAY, MCK and MMSI, in the dental space that have performed impressively despite the pandemic-led volatility.
XRAY vs. ALGN: Which Stock Is the Better Value Option?
by Zacks Equity Research
XRAY vs. ALGN: Which Stock Is the Better Value Option?
Here's Why You Should Hold on to NEOGEN (NEOG) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about NEOGEN (NEOG) on robust segmental and geographical growth.
Bruker Corporation (BRKR) Reports Solid Preliminary Q1 Revenues
by Zacks Equity Research
Bruker's (BRKR) revenue improvement in the first quarter is likely to have been boosted by robust performance by all three of its BSI groups.
PRA Health (PRAH) Chosen by MedChi to Offer Telehealth Services
by Zacks Equity Research
PRA Health's (PRAH) company, Care Innovations, gets selected by MedChi to provide remote patient monitoring services, thereby enabling better patient care.
Reasons to Hold on to Align Technology (ALGN) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Align Technology (ALGN) on solid customer adoption of Invisalign and iTero products.
Luminex (LMNX) to Get Acquired by DiaSorin for Around $1.8B
by Zacks Equity Research
Luminex (LMNX) to be acquired by DiaSorin for around $1.8 billion. This is likely to advance its technology and solutions' foothold outside the United States.
Here's Why You Should Hold on to Cardinal Health (CAH) Stock
by Zacks Equity Research
Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment and diversified product portfolio.
Here's Why You Should Add Phibro (PAHC) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Phibro (PAHC), owing to its potential in Performance Products and consistent high demand for its nutritional specialty products.
Globus Medical (GMED) Hurt by Dull Global Growth, Low Margins
by Zacks Equity Research
Pricing continues to remain a major headwind for Globus Medical (GMED).
Omnicell's (OMCL) Automated Dispensing Service Adopted by Aultman
by Zacks Equity Research
Omnicell's (OMCL) Autonomous Pharmacy vision receives another boost with the latest service adoption by Aultman.
Illumina (ILMN) Preliminary Q1 Revenues Rebound, '21 View Up
by Zacks Equity Research
Illumina's (ILMN) revenue improvement in the first quarter is likely to have been boosted by on-going business recovery.
Here's Why You Should Hold on to Bruker (BRKR) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Bruker (BRKR) on its slew of product launches and potential in the BSI Nano Group.
Quest Diagnostics (DGX) Divests Minority Share of Q2 Solutions
by Zacks Equity Research
Quest Diagnostics' (DGX) divestment of Q2 solutions to IQVIA will allow IQVIA to lead Q2 Solutions on the next stage of its journey in central lab services as a global leader.
Henry Schein's (HSIC) New Deal Boosts Ambulatory Surgery Market
by Zacks Equity Research
Henry Schein's (HSIC) recent majority ownership in Stradis Healthcare will advance the former's commitment to offer specialty solutions to customers.
Integra's (IART) Neurosurgery Rebounds Despite Supply Issues
by Zacks Equity Research
Integra LifeSciences (IART) is confident of achieving long-term goals of 5% to 7% revenue growth organically,
Illumina's (ILMN) Grail Merger in Trouble as FTC Files Suit
by Zacks Equity Research
According to FTC, the Illumina (ILMN) and Grail merger will diminish the scope of innovation in the U.S. market for MCED tests.
Surging Earnings Estimates Signal Upside for Dentsply (XRAY) Stock
by Zacks Equity Research
Dentsply (XRAY) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Why You Should Add DENTSPLY SIRONA (XRAY) to Your Portfolio
by Zacks Equity Research
Investor confidence is high in the DENTSPLY SIRONA (XRAY) stock, thanks to solid prospects.
DENTSPLY SIRONA's (XRAY) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in DENTSPLY SIRONA (XRAY).
Here's Why You Should Retain Cooper Companies (COO) Now
by Zacks Equity Research
Investors remain optimistic about Cooper Companies (COO) backed by strong CSI and CVI product portfolios and its continued leadership in the specialty lenses market.
Zacks Industry Outlook Highlights: McKesson Corp, West Pharmaceutical Services, Cardinal Health, Align Technology and Dentsply Sirona
by Zacks Equity Research
Zacks Industry Outlook Highlights: McKesson Corp, West Pharmaceutical Services, Cardinal Health, Align Technology and Dentsply Sirona
3 Stocks to Capitalize on Promising Dental Supplies Industry
by Trina Mukherjee
Despite the challenges thrown by the COVID-19 pandemic, teledentistry coupled with AI & Robotics should lend support to the Zacks Medical - Dental Supplies industry. MCK, WST and CAH are well-poised to gain from the prospects.
DENTSPLY SIRONA (XRAY) at a 52-Week High: What's Driving It?
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) is optimistic about growth in CAD/CAM business arm along with its recent product launch and strategic buyouts.